Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Vitrafy expands US blood partnerships and enters cell therapy market

VFY: $2.36 -2.07% · MC: $165M

Vitrafy added Versiti as its third US civilian blood partner and agreed to work with Charter Medical, extending its cryopreservation program into cell and gene therapy. Its partnerships now cover approximately 17% of US civilian blood collection sites, while partner device deployments are planned for the current quarter and US medical device listing remains on track for late 2026. The company ended the quarter with A$38 million in cash and term deposits.

Source announcements: 2026-10-28 08:17 to 2026-10-28 08:17 Sydney time
Story updated 2026-10-28 08:19 Sydney time
SourcesQ1 FY27 Quarterly Activities Report and Appendix 4CQuarterly Investor Briefing Presentation
Comments